Modulation of Intestinal Barrier Function and Inflammation Via Butyrate-promoting Dietary Fibre

Örebro University, Sweden40 enrolled

Overview

This study examines how a fermentable dietary fibre known to promote butyrate production impacts intestinal barrier function, intestinal microbiota, intestinal inflammation, and gastrointestinal symptoms in patients with microscopic colitis.

The study examines the effects of a 6-week supplementation period with a dietary fibre product (type of wheat bran) on intestinal barrier function, intestinal inflammation, intestinal microbiota, and gastrointestinal symptoms in patients with MC. The study subjects will consume the study products (placebo-fibre, butyrate-promoting fibre) as a powder supplemented to their daily habitual diet. A maltodextrin-based product is used as placebo. After giving their informed consent, the study subjects fill out a background questionnaire to assess their eligibility for the study (Visit 1). Participants deemed suitable for the study will be randomised into two study arms (placebo-fibre, butyrate-promoting fibre) before undergoing a baseline visit (Visit 2) before the start of the intervention period. After the 6-week intervention period, the participants will come back for a final visit (Visit 3). In vivo intestinal permeability will be measured using the standard multi-sugar test at visits 2 and 3. Blood and faecal samples will also be collected during visits 2 and 3. In addition to the visits described above, a subset of patients (max. 20) will undergo a colonoscopy before and at the end of the intervention period at Örebro University Hospital where an experienced gastroenterologist collects 16 colonic biopsies. These colonic biopsies are mounted in an Ussing chamber system to specifically study colonic permeability. During visits 2 and 3, the participants also complete questionnaires to assess their gastrointestinal symptoms, quality of life, physical activity, and dietary habits. During the study period, the participants will also keep a daily diary recording the number of diarrheal and loose stools. The participants are asked to maintain their habitual diet and lifestyle as well as not to consume probiotic or prebiotic supplements.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

QUADRUPLE

Enrollment

Conditions

Microscopic Colitis

Interventions

Dietary fibreDIETARY_SUPPLEMENT

Dietary fibre as a powder, 24 g per day for 6 weeks

Placebo compoundDIETARY_SUPPLEMENT

Maltodextrin powder, 24 g per day for 6 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Signed informed consent 2. Diagnosis of microscopic colitis (collagenous or lymphocytic colitis) 3. Active disease with no medication (e.g. budesonide) or stable budesonide treatment with or without symptoms 4. Age between 18-75 Exclusion Criteria: 1. Previous diagnosis of other organic gastrointestinal disease that interferes with the outcome parameters used in this study (e.g. ulcerative colitis) 2. Previous abdominal surgery which might influence gastrointestinal function, except appendectomy and cholecystectomy 3. History of or present gastrointestinal malignancy or polyposis 4. Diagnosis of gastrointestinal infection within the last 6 months 5. Current diagnosis of dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation 6. Chronic neurological/neurodegenerative disease (e.g. Parkinson's disease) 7. Autoimmune disease (e.g. rheumatoid arthritis) 8. Chronic pain syndromes (e.g. fibromyalgia) 9. Chronic fatigue syndrome 10. Severe endometriosis 11. Coeliac disease 12. Diagnosis of lactose intolerance within the last 3 months 13. Pregnancy or breast-feeding 14. Regular intake of anti-inflammatory and/or other immunosuppressive medication than budesonide within the last 3 months 15. Intake of proton pump inhibitors (e.g. omeprazol) within the last 4 weeks 16. Use of anti-depressants within the last 3 months 17. Regular intake of mast cell stabilizing drugs (e.g. sodium cromoglycate) within the last 3 months 18. Antimicrobial treatment within the last 12 weeks before baseline sampling 19. Antimicrobial prophylaxis (e.g. urinary tract infection) 20. Regular intake of probiotics, nutritional supplements, or herb products that might affect intestinal function within the last 4 weeks if the investigator considers that those could affect study outcome 21. Inability to maintain current diet and lifestyle during the study period 22. Alcohol or drug abuse 23. Any clinically significant present or past disease/condition which the investigator considers to possibly interfere with the study outcome

Locations (1)

Örebro University

Örebro, Örebro County, Sweden

RECRUITING

Outcomes

Primary Outcomes

Colonic permeability in vivo

Difference in urinary sucralose/erythritol excretion ratio between the study arms

Time frame: 6 weeks

Secondary Outcomes

Small intestinal permeability in vivo

Difference in urinary lactulose/rhamnose excretion ratio between the study arms

Time frame: 6 weeks

Colonic permeability ex vivo in Ussing chambers

Difference in the translocation of FITC-labeled dextran and horseradish peroxidase between the study arms

Time frame: 6 weeks

Concentrations of intestinal fatty-acid binding protein

Difference in plasma concentrations of intestinal fatty-acid binding protein between the study arms

Time frame: 6 weeks

Concentrations of lipopolysaccharide-binding protein

Difference in plasma levels of lipopolysaccharide-binding protein between the study arms

Time frame: 6 weeks

Concentratios of faecal calprotectin

Difference in faecal levels of calprotectin between the study arms

Time frame: 6 weeks

Concentrations of faecal myeloperoxidase

Difference in faecal levels of myeloperoxidase between the study arms

Time frame: 6 weeks

Concentrations of high-sensitive C-reactive protein

Difference in plasma levels of high-sensitive C-reactive protein between the study arms

Central Contacts

Richard A Forsgård, PhD

CONTACT

0790614037 richard.forsgard@oru.se

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.